NRx Pharmaceuticals responded to Kadima Neuropsychiatry Institute's public allegations regarding a failed acquisition by its subsidiary HOPE Therapeutics. The dispute centers on Kadima's failure to meet key closing conditions, leading to arbitration. NRx emphasizes that acquiring Kadima is not material to its business, which now focuses on advanced treatments like neuronavigated Transcranial Magnetic Stimulation combined with neuroplastic drugs. The company continues to advance clinical initiatives, including partnerships and FDA trial approvals, while distancing from Kadima's approach and ongoing litigation efforts.
Woodward, Inc. announced a quarterly cash dividend of $0.32 per share, payable on September 3, 2026, to shareholders of record as of August 20, 2026. This dividend reflects the company's ongoing commitment to returning value to shareholders. Woodward...
EShallGo Inc., a provider of integrated office technology solutions, completed a $1.479 million registered direct offering by selling 454,968 Class A shares at $3.25 each. The funds will support its growth in AI-enabled enterprise applications launch...
MEDIROM MOTHER Labs has expanded its deployment of the REMONY® remote health monitoring system, equipped with the recharge-free MOTHER Bracelet®, in the Japan Ground Self-Defense Force (JGSDF) 8th Division. The additional order triples the scale of t...
A new playground designed by kids and built by volunteers opened at Chimborazo Elementary School in Richmond, serving over 400 students and the wider community. Funded mainly by the CarMax Foundation and supported by KABOOM!, this project aims to add...
Equinox Gold has signed 20-year land access agreements with the three communities hosting its Los Filos Mine in Mexico, enabling the company to begin restarting heap leach operations and advancing technical studies for potential expansion, including ...
